Corcept Therapeutics

Senior Clinical Research Associate (Sr CRA)

Redwood City, California, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, BiotechnologyIndustries

Requirements

Candidates should possess a Bachelor’s degree in a scientific field such as biology, chemistry, or related disciplines, and have a minimum of 5 years of experience as a Clinical Research Associate (CRA) within the pharmaceutical or biotechnology industry. Strong knowledge of clinical trial regulations, including ICH guidelines and GCP, is essential, along with experience in managing clinical study activities and working with CROs. Familiarity with cortisol modulation and endocrinology is a plus.

Responsibilities

The Senior Clinical Research Associate will independently manage all clinical aspects of small to medium-sized clinical studies, or assume significant management responsibilities on larger studies, working closely with cross-functional teams, vendors, and sites to ensure compliance with protocols, GCPs, and SOPs. This role involves supporting protocol development, monitoring study activities, overseeing vendor performance, participating in study design reviews, and assisting with study timelines and budgets while ensuring adherence to corporate and departmental goals.

Skills

Clinical Research

ICH/GCP

SOPs

Protocol Development

Study Management

Vendor Management

Data Review

Timeline Development

Budget Management

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free